Physician profile
Tiffany C Randolph
NPI 1861636300
$132,750.61
in general payments reported to CMS, 2019-2025
40 companies · $36K in 2025
The $36K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $917 · 2020: $382 · 2021: $530 · 2022: $819 · 2023: $23K · 2024: $70K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $72K · Travel and Lodging: $29K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $4,954 · Education: $52.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $71,690.64 |
| Travel and Lodging | $28,705.86 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,700.02 |
| Food and Beverage | $4,954.26 |
| Education | $52.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $88,974.33 | 2021-2025 | Symplicity G3, Onyx Frontier |
| Edwards Lifesciences Corporation | $31,704.87 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Recor Medical INC | $7,259.26 | 2024-2025 | Paradise Renal Denervation System, Paradise Ultrasound Renal Denervation System |
| Amgen INC. | $1,091.18 | 2019-2025 | Repatha, Repatha |
| Heartflow, INC. | $376.82 | 2019 | |
| Novartis Pharmaceuticals Corporation | $366.53 | 2019-2024 | |
| Novo Nordisk INC | $260.56 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Irhythm Technologies, INC. | $257.06 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.41 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $247.14 | 2022-2025 | |
| Esperion Therapeutics, INC. | $240.23 | 2020-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $198.78 | 2019-2025 | Lifevest |
| Pfizer INC. | $183.93 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $157.77 | 2019-2023 | Brilinta |
| Boston Scientific Corporation | $147.16 | 2023-2025 | Watchman Flx, Watchman |
Show all 39 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Randolph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.